If you would like to submit feedback regarding any Health Tags direct all correspondence to:

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 6. (14 June 2008), pp. 1065-1073.Abstract Purpose  The accuracy of positron emission tomography (PET)/CT with choline for the detection of prostate cancer is not well established. We assessed the dependence of choline maximum standardized uptake values (SUVmax) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. Methods  In this prospective study, PET/CT with choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B). Results  In group A, based on a sextant analysis with a choline SUVmax cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUVmax and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P?, citeulike.org

Adv Exp Med Biol, Vol. 587 (2006), pp. 285-302.Molecular imaging has become during the last years in an important tool for supporting cancer diagnosis and prognosis. PET and SPECT are the most common molecular imaging techniques, although very promising and specific biological molecular agent contrast for CT and MRI are being recently developed. However, the above imaging techniques require exogenous contrast agents and usually a sole molecular image can be obtained at once. On the contrary, in vivo magnetic resonance spectroscopy (MRS), in particular 1H MRS can simultaneously provide several molecular images using endogenous metabolites. In addition to biochemical spatial information from molecular imaging spectroscopy, MRS can also provide average metabolite profile of the selected affected tissue region. Initially MRS, especially 1H MRS, was extensively applied to complete and improve the diagnosis and prognosis of central nervous system (CNS) pathologies, in particular brain tumors. However, during the last years the MRS applications have been extent to the diagnosis of different very common cancer types such as breast, prostate, colon carcinoma, and ovarian, among others. Likewise, MRS has been also used for lymph node assessment. In this contribution, the added value of MRS for the diagnosis, prognosis, and treatment selection of two different, important types of cancer: (1) brain tumors and (2) prostate, will be presented and discussed. Brain tumors are the leading cause of death in children under 15, and although in adults, brain cancers are proportionately less common than other cancers, it is a devastating disease with high mortality. There is a great need to increase our understanding of brain tumor biology to improve diagnosis and to develop new treatments. 1H MRS is currently the only noninvasive method that can be used to investigate molecular profile of brain tumors and also provide molecular images, more than six in one acquisition, of the distribution of chemicals in a tumor, which are also generally heterogeneous. A summary of the applications of 1H MRS to the in vivo diagnosis and prognosis of brain tumors will be presented. In addition, examples of metabolite limits, infiltration and high cellularity location for neurosurgery applications by MRS molecular images will be shown. Likewise, new ex vivo methods of studying the detailed biochemistry of tumor biopsies as metabolomic (high resolution magic angle spinning ) and transcriptomic (DNA microarrays) will be discussed as complementary to in vivo MRS (FP6 European project eTUMOR). A preliminary comparison between molecular images from PET and 1H MRS will be also presented. Finally, the application of 1H MRS to the improvement of prostate diagnosis and prognosis, the second leading cause of cancer death, will also discussed, with particular attention to the location cancer contribution from MRS molecular images.B Celda, D Monleón, MC Martínez-Bisbal, V Esteve, B Martínez-Granados, E Piñero, R Ferrer, J Piquer, L Martí-Bonmatí, J Cervera, citeulike.org

Neoplasia, Vol. 7, No. 7. (July 2005), pp. 678-687.Dawen Zhao, Lan Jiang, Eric Hahn, Ralph Mason, citeulike.org

The Prostate, Vol. 25, No. 1. (1994), pp. 19-28.In this study, it was investigated whether prostate tumor biological parameters correlate with metabolic profiles. 1H and 31P magnetic resonance spectra were acquired from perchloric acid extracts of seven Dunning R-3327 prostate tumor sublines. Several metabolic ratios, for example, phosphocholine/total phosphate, choline/total creatine, and inositol/total creatine, did not correlate specifically with one biological characteristic but, based on each of these ratios, the well-differentiated, nonmetastatic, and hormone-dependent sublines could be discriminated from the poorly differentiated or anaplastic, metastatic, and hormone-independent sublines. The glycerophosphoethanolamine/total phosphate, glycerophosphocholine/total phosphate, and phosphocreatine/total phosphate ratios correlated with differentiation grade, and the differences in glycerophosphorylglycerol/total phosphate ratio between metastatic and nonmetastatic sublines was highly significant. No correlation for hormonal sensitivity with any of the metabolites measured could be found, neither by 31P nor by 1H MRS. © 1994 Wiley-Liss, Inc.EB Cornel, A Heerschap, GAHJ Smits, GON Oosterhof, FMJ Debruyne, JA Schalken, citeulike.org

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, No. 8. (2007), pp. 1316-1317.Mohsen Beheshti, Reza Vali, Werner Langsteger, citeulike.org

Neoplasia, Vol. 9, No. 6. (June 2007), pp. 455-463.Zapotoczna, Aleksandra, Sasso, Giuseppe, Simpson, John, Roach, Mack, citeulike.org

Cancer Res, Vol. 66, No. 20. (15 October 2006), pp. 9929-9936.The integration of imaging technologies with the capabilities of genetic engineering has created novel opportunities for understanding and imaging cancer. Here, we have combined vascular magnetic resonance imaging (MRI) and optical imaging to understand the relationship between hypoxia and vascularization in a human prostate cancer model engineered to express enhanced green fluorescent protein (EGFP) under hypoxia. Characterization and validation of EGFP expression under hypoxic conditions was done in culture and in solid tumors in vivo. MRI measurements showed that vascular volume was significantly lower in fluorescing regions. These regions also frequently exhibited high permeability. These data were further supported by the detection of low vessel density in EGFP-positive regions, as determined by the distribution of intravascularly administered, fluorescence-labeled Lycopersicon esculentum lectin in frozen tumor sections. These observations are consistent with the possibility that regions of low vascular volumes are hypoxic, which induces increased expression of functionally active vascular endothelial growth factor, a potent vascular permeability factor. (Cancer Res 2006; 12(20): 9929-36) 10.1158/0008-5472.CAN-06-0886Venu Raman, Dmitri Artemov, Arvind Pathak, Paul Winnard, Stephen Mcnutt, Anna Yudina, Alexei Bogdanov, Zaver Bhujwalla, citeulike.org

"0360-3016" Posted by crispinHK to Misonidazole "Carcinoma,Non-Small-Cell Lung" Tomography,Emission-Computed Support,U.S.Gov't,P.H.S. "Fluorine Radioisotopes" "Cell Hypoxia" "radiation oncology" "diagnostic use" "Lung Neoplasms" "Prostatic Neoplasms" Pharmacokinetics Neoplasms "radionuclide imaging" physiopathology Male prostate metabolism human on Mon Dec 22 2008, connotea.org